Neuropathic pain therapeutic - Sphaera Pharma/Synthia Dermatech
Alternative Names: diclofenac sodium 1% + triclocarbanLatest Information Update: 18 Dec 2019
Price :
$50 *
At a glance
- Originator Sphaera Pharma
- Class Anti-infectives; Antipyretics; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Small molecules
- Mechanism of Action Cyclooxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Neuropathic pain
Most Recent Events
- 18 Dec 2019 No development reported - Phase-I/II for Neuropathic pain in India (Topical)
- 13 Apr 2016 Clinical development is ongoing for Neuropathic pain in India
- 31 Dec 2009 Sphaera Pharma enters into a collaboration with Synthia Dermatech for development of treatments for Neuropathic pain (Sphaera Pharma website, February 2016) before December 2016